Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B-cell Lymphoma: a Systematic Review

Overview

Journal Hematol Transfus Cell Ther

Specialty Hematology

Date 2024 Aug 1

PMID 39089933

Authors

Andressa Rodrigues Dos Santos

Daniela Zanini

Daniel Andolfatto

Affiliations

Soon will be listed here.

Abstract

Introduction: Chimeric antigen receptor T (CAR-T) cell therapy is an innovative technology that has shown promising results in clinical trials. Treatment is based on modifying the patient's own T cells to express artificial surface receptors to specifically recognize and attack the tumor cells.

Objective: To synthesize available evidence on the incidence and management strategies of cytokine release syndrome in patients with diffuse large B-cell lymphoma who received CAR-T cell therapy.

Methods: This is a systematic literature review. The search was conducted in the PubMed, Scopus, and Web of science databases. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The systematic review protocol is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database under number CRD42022359258.

Results: Nineteen studies were included with a total of 1193 patients who received CAR-T cell therapy. Of these patients, 804 (67%) developed some degree of cytokine release syndrome. The frequencies of Grade 3 and 4 cytokine release syndrome were 10% and 3%, respectively. The regimen most used in the management of the syndrome included tocilizumab and/or glucocorticoids.

Conclusion: The results obtained in this review demonstrate high rates of cytokine release syndrome in patients with diffuse large B-cell lymphoma treated with CAR-T cell therapy, however these events are manageable, supporting the conclusion that this therapy is safe in these patients.

References

Qu C, Zou R, Wang P, Zhu Q, Kang L, Ping N . Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. Front Immunol. 2022; 13:969660. PMC: 9429371. DOI: 10.3389/fimmu.2022.969660. View

Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O . Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022; 3(Suppl 1):39-45. PMC: 9175845. DOI: 10.1002/jha2.335. View

Brudno J, Kochenderfer J . Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017; 15(1):31-46. DOI: 10.1038/nrclinonc.2017.128. View

Cook M, Dorris C, Makambi K, Luo Y, Munshi P, Donato M . Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2022; 7(1):32-39. DOI: 10.1182/bloodadvances.2022008525. View

Neelapu S, Dickinson M, Munoz J, Ulrickson M, Thieblemont C, Oluwole O . Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022; 28(4):735-742. PMC: 9018426. DOI: 10.1038/s41591-022-01731-4. View

Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q . Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. J Immunother. 2019; 43(1):32-37. DOI: 10.1097/CJI.0000000000000284. View

Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz C . Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017; 9(9):1183-1197. PMC: 5582407. DOI: 10.15252/emmm.201607485. View

Sehgal A, Hoda D, Riedell P, Ghosh N, Hamadani M, Hildebrandt G . Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022; 23(8):1066-1077. DOI: 10.1016/S1470-2045(22)00339-4. View

Wang X, Riviere I . Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016; 3:16015. PMC: 4909095. DOI: 10.1038/mto.2016.15. View

10.

Kamdar M, Solomon S, Arnason J, Johnston P, Glass B, Bachanova V . Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim.... Lancet. 2022; 399(10343):2294-2308. DOI: 10.1016/S0140-6736(22)00662-6. View

11.

Han D, Xu Z, Zhuang Y, Ye Z, Qian Q . Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer. 2021; 12(2):326-334. PMC: 7738987. DOI: 10.7150/jca.48976. View

12.

Cao J, Wang H, Gao W, You J, Wu L, Wang Z . The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020; 22(4):214-226. DOI: 10.1016/j.jcyt.2020.01.015. View

13.

Goto H, Makita S, Kato K, Tokushige K, Fujita T, Akashi K . Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int J Clin Oncol. 2020; 25(9):1736-1743. PMC: 7441082. DOI: 10.1007/s10147-020-01699-6. View

14.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

15.

Anagnostou T, Riaz I, Hashmi S, Murad M, Kenderian S . Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020; 7(11):e816-e826. DOI: 10.1016/S2352-3026(20)30277-5. View

16.

Locke F, Neelapu S, Bartlett N, Siddiqi T, Chavez J, Hosing C . Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017; 25(1):285-295. PMC: 5363293. DOI: 10.1016/j.ymthe.2016.10.020. View

17.

Bastos-Oreiro M, Gutierrez A, Reguera J, Iacoboni G, Lopez-Corral L, Terol M . Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. Front Immunol. 2022; 13:855730. PMC: 9336530. DOI: 10.3389/fimmu.2022.855730. View

18.

Kedmi M, Shouval R, Fried S, Bomze D, Fein J, Cohen Z . Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplant Cell Ther. 2022; 28(5):251-257. PMC: 9519531. DOI: 10.1016/j.jtct.2022.02.017. View

19.

Cheng Q, Tan J, Liu R, Kang L, Zhang Y, Wang E . CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma. Cytotherapy. 2022; 24(10):1026-1034. DOI: 10.1016/j.jcyt.2022.05.001. View

20.

Huang C, Wu L, Liu R, Li W, Li Z, Li J . Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study. Ann Transl Med. 2020; 8(17):1048. PMC: 7575989. DOI: 10.21037/atm-20-4363. View